Olema Pharmaceuticals (OLMA) Competitors $5.43 +0.17 (+3.21%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA vs. HROW, VERA, ARDX, COGT, AVDL, CVAC, CALT, PAHC, NTLA, and AMPHShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Harrow (HROW), Vera Therapeutics (VERA), Ardelyx (ARDX), Cogent Biosciences (COGT), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Intellia Therapeutics (NTLA), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Olema Pharmaceuticals vs. Its Competitors Harrow Vera Therapeutics Ardelyx Cogent Biosciences Avadel Pharmaceuticals CureVac Calliditas Therapeutics AB (publ) Phibro Animal Health Intellia Therapeutics Amphastar Pharmaceuticals Harrow (NASDAQ:HROW) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk and volatility, HROW or OLMA? Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Do insiders and institutionals hold more shares of HROW or OLMA? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 15.2% of Harrow shares are owned by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation & earnings, HROW or OLMA? Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M7.19-$17.48M-$0.25-155.18Olema PharmaceuticalsN/AN/A-$129.47M-$1.98-2.72 Do analysts rate HROW or OLMA? Harrow currently has a consensus target price of $64.67, suggesting a potential upside of 66.69%. Olema Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 345.27%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Olema Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is HROW or OLMA more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.18% -0.35% Olema Pharmaceuticals N/A -42.58%-38.65% Does the media prefer HROW or OLMA? In the previous week, Harrow had 19 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 28 mentions for Harrow and 9 mentions for Olema Pharmaceuticals. Harrow's average media sentiment score of 0.79 beat Olema Pharmaceuticals' score of 0.36 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 3 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHarrow beats Olema Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$369.92M$3.13B$5.69B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-2.7220.6930.6725.54Price / SalesN/A369.66463.88116.75Price / CashN/A43.0338.2159.48Price / Book1.078.578.986.13Net Income-$129.47M-$54.65M$3.25B$264.89M7 Day Performance16.16%6.51%4.75%2.74%1 Month Performance17.43%9.41%6.74%3.14%1 Year Performance-56.50%14.15%30.55%25.31% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals1.6493 of 5 stars$5.39+2.5%$24.00+345.3%-56.2%$369.92MN/A-2.7270News CoverageEarnings ReportAnalyst ForecastHROWHarrow2.6364 of 5 stars$33.74-2.0%$63.83+89.2%+8.0%$1.26B$199.61M-60.25180Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeVERAVera Therapeutics3.5924 of 5 stars$20.17+1.9%$63.00+212.3%-43.9%$1.26BN/A-5.6340ARDXArdelyx4.417 of 5 stars$5.40+3.6%$11.50+113.0%+2.8%$1.26B$333.61M-23.4890Options VolumeCOGTCogent Biosciences3.4355 of 5 stars$10.93-0.3%$18.70+71.1%+37.4%$1.25BN/A-6.1480AVDLAvadel Pharmaceuticals2.8344 of 5 stars$12.79+0.3%$18.67+45.9%-14.2%$1.23B$169.12M-426.3370CVACCureVac4.4092 of 5 stars$5.43-0.2%$6.83+25.8%+66.5%$1.22B$579.18M5.90880News CoverageUpcoming EarningsShort Interest ↓CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoveragePAHCPhibro Animal Health3.7189 of 5 stars$28.54+1.6%$24.40-14.5%+75.8%$1.14B$1.02B36.591,940NTLAIntellia Therapeutics4.517 of 5 stars$10.74-0.5%$30.68+185.7%-49.3%$1.12B$57.88M-2.29600Analyst ForecastAnalyst RevisionAMPHAmphastar Pharmaceuticals3.2156 of 5 stars$27.36+14.9%$30.00+9.6%-28.8%$1.11B$731.97M10.252,028Analyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies HROW Alternatives VERA Alternatives ARDX Alternatives COGT Alternatives AVDL Alternatives CVAC Alternatives CALT Alternatives PAHC Alternatives NTLA Alternatives AMPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OLMA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access